Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies
Numerically higher proportions of bimekizumab-treated patients achieved concurrent complete skin and nail clearance versus adalimumab, ustekinumab, and secukinumab. Clearance rates increased following switch to bimekizumab, and were sustained long-term in both switchers to bimekizumab and continuous bimekizumab-treated patients. [Graphical abstract available.] CLINICAL TRIAL REGISTRATION: NCT03412747, NCT03370133, NCT03598790, NCT03536884.
Authors
- Bengt Hoepken (ORCID: https://orcid.org/0000-0002-7487-8559)
- Kenneth B. Gordon (ORCID: https://orcid.org/0000-0002-9347-0292)
- Sarah Kavanagh (ORCID: https://orcid.org/0000-0003-0341-8261)
- Emi Nishida (ORCID: https://orcid.org/0000-0001-6563-1274)
- Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
- Curdin Conrad (ORCID: https://orcid.org/0000-0002-2547-3440)
- José Manuel López Pinto
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
- Paolo Gisondi (ORCID: https://orcid.org/0000-0002-1777-9001)
- Bruce E Strober (ORCID: https://orcid.org/0000-0002-8394-2057)
Institutions
- University of Verona (IT)
- Medical College of Wisconsin (US)
- Manchester Academic Health Science Centre (GB)
- University of Manchester (GB)
- Northern Health and Social Care Trust (GB)
- Yale University (US)
- Nagoya City University (JP)
- Central Dermatology (US)
- Nagoya Medical Center (JP)
- UCB Pharma (Germany) (DE)
- The University of Texas Southwestern Medical Center (US)
- University of Lübeck (DE)
Publication Details
- Journal
- American Journal of Clinical Dermatology
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1007/s40257-025-00968-2
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Celgene
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- Dermira
- Incyte
- National Institute for Health and Care Research
- Meiji Seika Pharma
- Galderma
- Sun Pharma
- LEO Pharma
- Samsung
- Sanofi Genzyme
- Manchester Biomedical Research Centre
- Daiichi Sankyo Europe